750 related articles for article (PubMed ID: 32165253)
1. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma.
Kim N; Kim HJ; Won JY; Kim DY; Han KH; Jung I; Seong J
Radiother Oncol; 2019 Feb; 131():81-87. PubMed ID: 30773192
[TBL] [Abstract][Full Text] [Related]
3. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.
Wang F; Numata K; Takeda A; Ogushi K; Fukuda H; Nihonmatsu H; Hara K; Chuma M; Tsurugai Y; Maeda S
BMC Cancer; 2021 Oct; 21(1):1169. PubMed ID: 34717577
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma.
Shin HS; Hwan Lee S; Jun BG; Kim HS; Kang SH; Park JY; Choi SI; Cheon GJ; Kim YD; Yoo JJ; Kim SG; Kim YS; Jeong SW; Jang JY; Suk KT; Kim DJ; Jo IY; Won YK
Eur J Gastroenterol Hepatol; 2022 Nov; 34(11):1187-1194. PubMed ID: 36170689
[TBL] [Abstract][Full Text] [Related]
5. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
6. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
[TBL] [Abstract][Full Text] [Related]
7. Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma.
Suh YJ; Jin YJ; Jeong Y; Shin WY; Lee JM; Cho S; Yu JH; Lee JW
Medicine (Baltimore); 2021 Oct; 100(43):e27470. PubMed ID: 34713824
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma.
Shen PC; Chang WC; Lo CH; Yang JF; Lee MS; Dai YH; Lin CS; Fan CY; Huang WY
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):307-318. PubMed ID: 31175903
[TBL] [Abstract][Full Text] [Related]
9. Radiofrequency ablation versus stereotactic body radiation therapy for small (≤ 3 cm) hepatocellular carcinoma: A retrospective comparison analysis.
Jeong Y; Lee KJ; Lee SJ; Shin YM; Kim MJ; Lim YS; Lee HC; Jung J; Park JH; Kim JH; Kim SY; Yoon SM
J Gastroenterol Hepatol; 2021 Jul; 36(7):1962-1970. PubMed ID: 33594690
[TBL] [Abstract][Full Text] [Related]
10. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis.
Jun BG; Kim SG; Kim YD; Cheon GJ; Han KH; Yoo JJ; Kim YS; Jeong SW; Jang JY; Lee SH; Park S; Kim HS
PLoS One; 2018; 13(10):e0206381. PubMed ID: 30379885
[TBL] [Abstract][Full Text] [Related]
12. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
Kuo MJ; Mo LR; Chen CL
BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases.
Jackson WC; Tao Y; Mendiratta-Lala M; Bazzi L; Wahl DR; Schipper MJ; Feng M; Cuneo KC; Lawrence TS; Owen D
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):950-958. PubMed ID: 29485074
[TBL] [Abstract][Full Text] [Related]
14. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
Wahl DR; Stenmark MH; Tao Y; Pollom EL; Caoili EM; Lawrence TS; Schipper MJ; Feng M
J Clin Oncol; 2016 Feb; 34(5):452-9. PubMed ID: 26628466
[TBL] [Abstract][Full Text] [Related]
15. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies.
Kibe Y; Takeda A; Tsurugai Y; Eriguchi T
Acta Oncol; 2020 Aug; 59(8):888-894. PubMed ID: 32216593
[No Abstract] [Full Text] [Related]
16. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma.
Ji R; Ng KK; Chen W; Yang W; Zhu H; Cheung TT; Chiang CL; Wong TCL; Kong FM; Wu G; Lo CM
Medicine (Baltimore); 2022 Jan; 101(4):e28545. PubMed ID: 35089192
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.
Takeda A; Sanuki N; Tsurugai Y; Iwabuchi S; Matsunaga K; Ebinuma H; Imajo K; Aoki Y; Saito H; Kunieda E
Cancer; 2016 Jul; 122(13):2041-9. PubMed ID: 27062278
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.
Sapisochin G; Barry A; Doherty M; Fischer S; Goldaracena N; Rosales R; Russo M; Beecroft R; Ghanekar A; Bhat M; Brierley J; Greig PD; Knox JJ; Dawson LA; Grant DR
J Hepatol; 2017 Jul; 67(1):92-99. PubMed ID: 28257902
[TBL] [Abstract][Full Text] [Related]
19. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.
Rajyaguru DJ; Borgert AJ; Smith AL; Thomes RM; Conway PD; Halfdanarson TR; Truty MJ; Kurup AN; Go RS
J Clin Oncol; 2018 Feb; 36(6):600-608. PubMed ID: 29328861
[TBL] [Abstract][Full Text] [Related]
20. Radiofrequency ablation versus stereotactic body radiotherapy for hepatocellular carcinoma: a meta-analysis.
Zhang H; Chang N; Han T; Ma S; Qu G; Liu H; Sun C; Cheng C; Zhou Q; Sun Y
Future Oncol; 2021 Oct; 17(30):4027-4040. PubMed ID: 34278818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
